Next-Gen RNA Therapies Fuel Market Expansion Across Oncology and Rare Diseases

RNA Therapeutics Market

Press Release Apr 24, 2025 22 Add to Reading List

"RNA Therapeutics Market Size, Share, and Trends Analysis Report—Industry Overview and Forecast to 2031

The RNA-Based Drug Market is witnessing significant growth, driven by evolving consumer demands, technological advancements, and expanding global trade. Leading market research companies indicate that the mRNA Therapy Market is expected to experience steady expansion in the coming years, fueled by increased investments and innovation. Businesses are increasingly relying on market insights to stay competitive in the siRNA Therapy Market, making data-driven decisions essential. With a growing focus on sustainability and efficiency, the RNA Interference Market is adapting to new trends that reshape industry dynamics. Comprehensive reports from top research firms highlight the critical role of analytics and strategic planning in the Gene Silencing Market.

The RNA Therapeutics Market is poised for significant growth, with a market outlook highlighting substantial growth potential driven by emerging opportunities in key sectors. This report provides strategic insights, demand dynamics, and revenue projections, offering a comprehensive view of the future landscape, technology disruptions, and adoption trends shaping the industry’s ecosystem evaluation. According to Data Bridge Market Research The global RNA therapeutics market size was valued at USD 6.23 billion in 2023 and is projected to reach USD 16.80 billion by 2031, with a CAGR of 13.20% during the forecast period of 2024 to 2031.

With increasing globalization and digital disruption, the Nucleic Acid Therapeutics Market is expanding across multiple industries, including [industry name]. Market research data indicates that businesses in the Antisense Oligonucleotide Market are adopting sustainable practices and improving supply chain management to optimize operations. Companies operating in the RNA Editing Technologies Market are investing heavily in R&D, strategic partnerships, and innovative solutions to cater to changing market needs. As competition intensifies, firms in the Non-Coding RNA Therapy Market rely on expert insights and market analysis to identify growth opportunities. The RNA-Targeted Small Molecules Market continues to evolve, shaping new business strategies and industry trends worldwide.

Our comprehensive RNA Therapeutics Market report is ready with the latest trends, growth opportunities, and strategic analysis. https://www.databridgemarketresearch.com/reports/global-rna-therapeutics-market

**Segments**

- **Type:** The RNA therapeutics market can be segmented by type into mRNA, siRNA, miRNA, antisense RNA, and others. mRNA therapeutics, especially with the success of COVID-19 mRNA vaccines, are gaining traction for various diseases. Meanwhile, siRNA and miRNA are being explored for their potential in targeting specific genes for therapeutic purposes.

- **Application:** Based on application, the market can be divided into oncology, cardiovascular, infectious diseases, genetic disorders, and others. The oncology segment dominates the market due to the significant potential of RNA therapeutics in targeting cancer cells specifically.

- **Route of Administration:** RNA therapeutics market can also be segmented by the route of administration, including pulmonary, intravenous, intradermal, and others. The pulmonary route is becoming increasingly popular as it offers the advantage of direct delivery to the target site, especially for respiratory-related disorders.

**Market Players**

- **Moderna, Inc.:** Moderna is a prominent player in the RNA therapeutics market, known for its mRNA technology platform and the successful development of the COVID-19 vaccine. The company continues to expand its pipeline for various diseases beyond infectious diseases.

- **Pfizer Inc.:** Pfizer, in collaboration with BioNTech, developed one of the first mRNA-based COVID-19 vaccines. The success of this vaccine has propelled Pfizer as a key player in the RNA therapeutics market, with ongoing developments in other therapeutic areas.

- **Alnylam Pharmaceuticals, Inc.:** Alnylam focuses on RNA interference (RNAi) therapeutics, with several products in its pipeline for rare genetic diseases. The company's expertise in RNAi technology positions it well in the market.

- **Arrowhead Pharmaceuticals, Inc.:** Arrowhead is a leading player in developing RNAi-based therapeutics for various diseases, including liver-related disorders. The company's robust pipeline and partnerships contribute to its market presence.

- **Dicerna Pharmaceuticals, Inc.:**RNA therapeutics market is witnessing significant growth and innovation, driven by advancements in technology and increasing demand for more targeted and effective treatment options across various disease areas. The market segmentation based on type highlights the diverse applications of RNA therapeutics, with mRNA therapeutics leading the way, particularly after the successful development of COVID-19 mRNA vaccines. This success has propelled the exploration of mRNA for other diseases, showcasing the versatility and potential of this technology. Additionally, siRNA and miRNA therapeutics are gaining attention for their ability to target specific genes, opening up new avenues for personalized medicine and targeted therapy.

In terms of application, oncology stands out as the dominant segment in the RNA therapeutics market, owing to the precision and specificity that RNA-based therapies offer in targeting cancer cells. The ability to tailor treatments to individual genetic profiles and disease characteristics makes RNA therapeutics a promising avenue for addressing the complexity of cancer. Furthermore, the market segmentation based on the route of administration emphasizes the importance of targeted delivery methods, with the pulmonary route emerging as a preferred option for its direct delivery to the lungs, especially in the context of respiratory diseases.

Key market players, such as Moderna, Inc., Pfizer Inc., Alnylam Pharmaceuticals, Inc., Arrowhead Pharmaceuticals, Inc., and Dicerna Pharmaceuticals, Inc., are driving innovation and shaping the landscape of RNA therapeutics with their cutting-edge technologies and robust pipelines. Moderna and Pfizer's success in developing mRNA-based COVID-19 vaccines has not only validated the potential of mRNA therapeutics but has also positioned them as key players in the market with expanded focus beyond infectious diseases. Alnylam and Arrowhead's expertise in RNA interference (RNAi) therapeutics has led to the development of novel treatments for rare genetic diseases and liver-related disorders, showcasing the versatility of RNA-based approaches in addressing unmet medical needs.

Overall, the RNA therapeutics market is poised for continued growth and evolution, fueled by ongoing research and development efforts, strategic partnerships, and increasing recognition of the**Market Players**

Quark Software Inc.
Alnylam Pharmaceuticals, Inc.
Dicerna Pharmaceuticals, Inc.
Tekmira Pharmaceuticals
Arbutus Biopharma
Benitec Biopharma
Sanofi
Ionis Pharmaceuticals
Silence Therapeutics
Cenix BioScience
Sirnaomics
CureVac AG
BIONTECH SE
Arrowhead Pharmaceuticals, Inc.
Adhera Therapeutics
Marina Biotech, Inc.

The RNA therapeutics market is experiencing significant growth and innovation driven by advancements in technology and the increasing demand for more targeted and effective treatment options across various disease areas. The segmentation of the market based on type showcases the diverse applications of RNA therapeutics, with mRNA leading the way, particularly post the success of COVID-19 mRNA vaccines. This success has opened up avenues for exploring mRNA for other diseases, highlighting the versatility and potential of this technology. Additionally, the focus on siRNA and miRNA therapeutics is growing due to their ability to target specific genes, paving the way for personalized medicine and targeted therapy.

The oncology segment remains a key driver in the RNA therapeutics market, benefiting from the precision and specificity that RNA-based therapies offer in targeting cancer cells. The ability to customize treatments based on individual genetic profiles and disease characteristics positions RNA therapeutics as a promising solution for the complexities of cancer treatment. Moreover, the market segmentation based on the route of administration underscores the significance of targeted delivery methods, with the pulmonary route gaining traction for

The market is highly fragmented, with a mix of global and regional players competing for market share. To Learn More About the Global Trends Impacting the Future of Top 10 Companies in RNA Therapeutics Market : https://www.databridgemarketresearch.com/reports/global-rna-therapeutics-market/companies

Key Questions Answered by the Global RNA Therapeutics Market Report:

What are the global trends in the RNA Therapeutics Market?
Will the market witness an increase or decline in demand in the coming years?
What is the estimated demand for different types of products in the RNA Therapeutics Market?
What are the upcoming industry applications and trends for the RNA Therapeutics Market?
What are projections of the global RNA Therapeutics Market industry considering capacity, production, and production value?
What will be the estimated cost and profit? What will be the market share, supply, and consumption? What about import and export?
Where will strategic developments take the industry in the mid to long term?
What factors contribute to the final price of RNA Therapeutics Market products?
What are the key raw materials used in RNA Therapeutics Market manufacturing?
How big is the opportunity for the RNA Therapeutics Market?
How do industry statistics reflect recent changes in consumer behavior?
What are the top emerging industry trends shaping the future of the RNA Therapeutics Market?